Company Profile
Simulations Plus Stock Price, News & Catalysts
- Ticker:
- SLP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
18.40 USD (0.00%)
Close
Last updated: August 24, 2026
339M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, SLP was little changed and closed at $18.40. No new same-company headline was identified in the current news window.
Company overview
Business overview
Simulations Plus is a software company that provides modeling, simulation, and workflow tools for drug development. Its value lies in helping biopharma customers make better development decisions.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Simulations Plus sits in pharma software and development tools.
Business Model Characteristics
The company depends on software subscriptions, services, and continued adoption by drug developers and regulators.
Position Within the Biotechnology Landscape
Simulations Plus is an important biotech-enabling software name, not a drug company itself.
Future catalysts
- Simulations Plus's catalysts are software bookings, biosimulation demand, and AI-driven workflow adoption in pharma development. Investors will want to see whether the modeling platform stays embedded in drug development workflows.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Simulations Plus (SLP)?
Simulations Plus (SLP) most recently closed at 18.40 USD, a 0.00% move versus the previous session.
What is the market cap of Simulations Plus (SLP)?
Simulations Plus currently has a market capitalization of 339M USD on BioPharmSignal.
What does Simulations Plus do?
Simulations Plus is a software company that provides modeling, simulation, and workflow tools for drug development. Its value lies in helping biopharma customers make better development decisions.
On which exchange is SLP stock listed?
Simulations Plus (SLP) is associated with NASDAQ, United States, Biopharma.
What is Simulations?
Simulations Plus's catalysts are software bookings, biosimulation demand, and AI-driven workflow adoption in pharma development.
Which conditions is Simulations Plus targeting with Simulations?
Simulations Plus's catalysts are software bookings, biosimulation demand, and AI-driven workflow adoption in pharma development.
How does Simulations Plus describe recent progress with Simulations?
Simulations Plus's catalysts are software bookings, biosimulation demand, and AI-driven workflow adoption in pharma development.
What is Plus?
Simulations Plus is a software company that provides modeling, simulation, and workflow tools for drug development.